使用Gammanorm(®)治疗原发性和继发性免疫缺陷及免疫介导疾病的临床经验。
Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
作者信息
Gardulf Ann
机构信息
The Unit for Clinical Nursing Research & Clinical Research in Immunotherapy, Division of Clinical Immunology, Department of Laboratory Medicine and Transfusion Medicine, Karolinska Institutet, SE-141 83 Huddinge, Stockholm, Sweden.
The Japanese Red Cross Institute for Humanitarian Studies, Tokyo, Japan.
出版信息
Immunotherapy. 2016 May;8(5):633-47. doi: 10.2217/imt-2015-0013. Epub 2016 Mar 29.
Treatment for primary and secondary immunodeficiency disorders focuses on prevention and management of infections, using immunoglobulin G (IgG) replacement therapy with regular intravenous or subcutaneous IgG (SCIG) infusions. SCIG therapy has many advantages including improved efficacy and tolerability, enhanced patient satisfaction and lower costs. A number of SCIG preparations are available, including Gammanorm(®) (Octapharma AG), a ready-to-use 16.5% liquid preparation of IgG, with low viscosity, well suited to self-administration and a long history of use. Clinical experience with Gammanorm has shown that it is effective and well tolerated in children and adults, including pregnant women, for primary and secondary immunodeficiency disorders. Recent data also suggest SCIG may have a role in the treatment of certain immune-mediated conditions.
原发性和继发性免疫缺陷疾病的治疗重点在于预防和控制感染，采用免疫球蛋白G（IgG）替代疗法，定期进行静脉注射或皮下注射IgG（SCIG）。SCIG疗法具有诸多优势，包括疗效提高、耐受性增强、患者满意度提升以及成本降低。有多种SCIG制剂可供选择，包括Gammanorm(®)（奥克特珐玛公司），这是一种即用型16.5%的IgG液体制剂，粘度低，非常适合自我给药，且使用历史悠久。Gammanorm的临床经验表明，它在儿童和成人（包括孕妇）中对于原发性和继发性免疫缺陷疾病有效且耐受性良好。近期数据还表明，SCIG可能在某些免疫介导疾病的治疗中发挥作用。
Zotero 插件